Latigo Biotherapeutics (NASDAQ:LTGO) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

LTGO has been the subject of a number of other reports. Leerink Partners assumed coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 target price for the company. Jefferies Financial Group started coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective on the stock. Guggenheim started coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price for the company. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Latigo Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $52.25.

Latigo Biotherapeutics Price Performance

Latigo Biotherapeutics stock opened at $23.04 on Friday. Latigo Biotherapeutics has a twelve month low of $17.22 and a twelve month high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO) last announced its quarterly earnings results on Thursday, September 3rd. The company reported ($27.59) earnings per share (EPS) for the quarter.

Insider Activity

In related news, Director James B. Tananbaum acquired 140,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider directly owned 2,008,024 shares in the company, valued at $36,144,432. This represents a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.